NCT01331746已完成2 期
Randomised, Double-blind, Placebo-controlled Phase II Proof-of-concept Study of APD515 Solution for Oromucosal and Oral Administration for Relief of Xerostomia in Patients With Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 11
- 主要终点
- Xerostomia score
研究概览
简要总结
A study to look at the effectiveness of a drug called APD515, designed to be applied to the lining inside the mouth, at relieving dryness of the mouth. Study will compare one week of treatment with APD515 to one week of treatment with matching placebo to see which has better effect on patient's mouth dryness, according to their own score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥ 18 years
- •Able and willing to give written informed consent.
- •Confirmed primary neoplasm at any site (apart from non-melanoma skin cancers), for which first-line cytotoxic therapy has been completed more than one month prior to study entry. Ongoing palliative, hormonal, cytostatic or "targeted" (e.g., monoclonal antibody, tyrosine kinase inhibitor, etc) therapy is permitted, provided that the risk of oral mucositis in the subject is not judged to be significant.
- •Subjective complaint of dry mouth, ongoing for at least two weeks prior to study entry.
- •Capacity for salivary stimulation, as demonstrated by stimulated whole saliva flow rate > unstimulated whole saliva flow rate.
- •Karnofsky performance score ≥ 60% or ECOG performance status ≤
- •Adequate renal and hepatic function and hydration status:
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 * upper limit normal (ULN);
- •Serum urea < 1.5 * ULN and serum urea:creatinine ratio < 100 (where urea and creatinine expressed in the same units);
- •Plasma sodium ≤ ULN.
- •Adequate haematological function:
- •Haemoglobin ≥ 9 g/dL;
- •White blood count ≥ 1.0 * 10^9/L;
- •Platelet count ≥ 50 *x 10^9/L.
- •For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards.
排除标准
- •Confirmed diagnosis of Sjögren's syndrome.
- •Prior radiotherapy for head & neck cancer, or other substantial doses of radiation delivered to the area of the mouth or salivary glands.
- •Significant, symptomatic disease of the oral cavity, including oral candidosis or oral mucositis.
- •Allergy to active ingredient or any of the excipients of APD
- •Use of oral or topical (including ocular) pilocarpine or cevimeline in the two weeks prior to enrolment.
- •Concomitant use of procainamide, quinidine or ganglionic blocking agents such as mecamylamine, pentolinium and trimethaphan.
- •Intestinal or urinary obstruction.
- •Myocardial infarction or intestinal anastomosis within the previous 6 months.
- •Participation in an investigational drug or device study within 1 month prior to study entry.
- •For female subjects only, a positive pregnancy test.
- •Any condition or disease detected during the medical interview/physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.
研究组 & 干预措施
APD515
Experimental
Active APD515 treatment 20 mg qds for 7 days
干预措施: APD515 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Xerostomia score
时间窗: 1 week
Change in score on 100 mm visual analogue scale
次要结局
未报告次要终点
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
CyPep-1 in Cutaneous WartsCutaneous WartsNCT03846648Centre for Human Drug Research, Netherlands56
已完成
2 期
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)SchizophreniaParanoid SchizophreniaNCT00482430Merck Sharp & Dohme LLC50
已完成
1 期
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy VolunteersHealthy Volunteer StudyNCT06757738Traws Pharma, Inc.66
已完成
1 期
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy VolunteersHealthy Volunteers OnlyNCT06402136Traws Pharma, Inc.57
已完成
2 期
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's SyndromePrimary Sjögren's SyndromeNCT02775916Novartis Pharmaceuticals30